


## R1487 Hydrochloride

Cat. No.:	HY-14975
CAS No.:	449808-64-4
Molecular Formula:	C <sub>19</sub> H <sub>19</sub> ClF <sub>2</sub> N <sub>4</sub> O <sub>3</sub>
Molecular Weight:	424.83
Target:	p38 MAPK; Autophagy
Pathway:	MAPK/ERK Pathway; Autophagy
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 20.83 mg/mL (49.03 mM; Need ultrasonic)						
	H <sub>2</sub> O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)						
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg	
				1 mM	2.3539 mL	11.7694 mL	23.5388 mL
				5 mM	0.4708 mL	2.3539 mL	4.7078 mL
10 mM				0.2354 mL	1.1769 mL	2.3539 mL	
Please refer to the solubility information to select the appropriate solvent.							
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.90 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.90 mM); Clear solution						

### BIOLOGICAL ACTIVITY

Description	R1487 Hydrochloride is a highly potent and selective p38α inhibitor, with K <sub>d</sub> values of 0.2 nM and 29 nM for p38α and p38β, respectively <sup>[1]</sup> .	
IC <sub>50</sub> & Target	p38α 0.2 nM (K <sub>d</sub> )	p38β 29 nM (K <sub>d</sub> )
In Vitro	R1487 Hydrochloride exhibits IC <sub>50</sub> values of 10 nM for p38α inhibition and 200 nM for the inhibition of TNFα induced production of IL-1β <sup>[1]</sup> . R1487 (Compounds 2a) inhibits production of TNFα by human monocytic cells (THP-1) and inhibits production of IL-1β in human whole blood (HWB) induced by LPS <sup>[1]</sup> .	

---

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**In Vivo**

R1487 (Compounds 2a, orally) demonstrates significant dose-dependent inhibition of serum TNF $\alpha$  and IL-1 $\beta$ <sup>[1]</sup>.  
Oral bioavailability of 10 mg/kg R1487 (Compounds 2a) in monkey, rat, and dog was 51.6%, 29.3%, 10.3%, respectively<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

**REFERENCES**

[1]. Goldstein DM et al. Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-on

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA